Physiology‐based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P‐glycoprotein induction and concurrent inhibition
Physiology‐based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P‐glycoprotein induction and concurrent inhibition
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now